Switch to:
More From Other Websites
Pfizer Phase 3 Study Of Inotuzumab Ozogamicin Meets Primary Endpoint In Adult Patients With Relapsed... Apr 21 2015
8:02 am Pfizer Phase 3 study investigating the treatment of inotuzumab ozogamicin met its first... Apr 21 2015
Pfizer Phase 3 Study Of Inotuzumab Ozogamicin Meets Primary Endpoint In Adult Patients With Relapsed... Apr 21 2015
AQR Capital Ups Stake in Johnson and Johnson Apr 20 2015
Mylan–Perrigo Merger: What Are the Long-Term Growth Drivers? Apr 20 2015
Cuomo's headed for Cuba, but don't expect a 'Nixon goes to China' moment Apr 20 2015
The Zacks Analyst Blog Highlights: Powershares Dynamic Pharmaceuticals ETF, SPDR S&P Pharmaceuticals... Apr 20 2015
Global Strategic Partners Merck KGaA, Darmstadt, Germany, and Pfizer Initiate Phase III Study with... Apr 20 2015
Global Strategic Partners Merck and Pfizer Initiate Phase III Study with Avelumab in Patients with... Apr 20 2015
Global Strategic Partners Merck KGaA, Darmstadt, Germany, and Pfizer Initiate Phase III Study with... Apr 20 2015
NY's Cuomo to be first gov. to visit Cuba as ties reopen Apr 19 2015
NY's Cuomo to be first gov. to visit Cuba as ties reopen Apr 19 2015
Future UK Labour government will give workers a say on the boss's pay Apr 19 2015
Targacept's Diabetic Gastroparesis Drug Fails to Impress - Analyst Blog Apr 17 2015
Pfizer Wins First Trial Over Zoloft Birth-Defect Claims Apr 17 2015
Pfizer wins first U.S. trial over Zoloft birth-defect risk Apr 17 2015
Teva Getting Serious About Mylan Bid, Says Report Apr 17 2015
Pfizer Jury Told Zoloft Risks Known But Hidden From Patients Apr 17 2015
A Beginner's Guide to Pharma ETFs - ETF News And Commentary Apr 17 2015
Dorset Management Made a Bundle By Betting on Biotech and Energy; More Profits to Come? Apr 17 2015


Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

SEENSCO
ReplySEENSCO - 10 months ago
PFE is trading at the low end of our short-term valuation range ($29-$36) and significantly below our Fair Value estimate of $42.41.


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK